GLAXOSMITHKLINE PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,133 INR | +3.26% |
|
+14.12% | +12.40% |
| Apr. 25 | GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology | RE |
| Mar. 22 | GlaxoSmithKline Pharmaceuticals Limited Receives Orders from Government Authorities | CI |
Presenter SpeechUnknown Executive (Executives)Good evening, and a warm welcome for those of yo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
Sector
Pharmaceuticals
Calendar
2024-05-16
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
2,133
INR
Average target price
2,141
INR
Spread / Average Target
+0.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.40% | 4.33B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- GLAXO Stock
- News GlaxoSmithKline Pharmaceuticals Limited
- Transcript : GlaxoSmithKline Pharmaceuticals Limited - Shareholder/Analyst Call
